NCT06731959View on ClinicalTrials.gov

A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

January 31, 2026

Conditions
COPD
Interventions
DRUG

Flexlamose

Fexlamose solution via nebulizer for 28 days

DRUG

Placebo

Placebo solution via nebulizer for 28 days

Sponsors

Lead Sponsor

Aer Therapeutics
All Listed Sponsors
lead

Aer Therapeutics

INDUSTRY